Winearls C G
Squibb Senior Lecturer in Medicine, Royal Postgraduate Medical School, London, UK.
Nephron. 1989;51 Suppl 1:26-8. doi: 10.1159/000185567.
Recombinant human erythropoietin (r-HuEPO) has been used for the treatment of renal anaemia in haemodialysed patients for more than 2 years. The recommended initial dose is 50 U/kg, intravenously, three times a week, subsequent to the dialysis procedure; if the increase in the haemoglobin level were insufficient after the 4-week therapy, the single doses should be elevated in steps of 25 U/kg each. A weekly total dose of about 200 U/kg (divided into 2 or 3 applications) will normally be adequate to stabilize the haemoglobin value at a level ranging between 10 and 12 g/dl. Patients on r-HuEPO require regular medical supervision, as--along with increasing haematocrit--hypertension and thrombosis of the arteriovenous fistula can develop. A slight increase in serum creatinine and potassium was observed in some of the studies.
重组人促红细胞生成素（r-HuEPO）已用于血液透析患者的肾性贫血治疗超过2年。推荐的初始剂量为50 U/kg，静脉注射，每周3次，在透析程序之后；如果4周治疗后血红蛋白水平升高不足，则单次剂量应每次以25 U/kg的幅度逐步提高。通常每周总剂量约200 U/kg（分为2次或3次给药）足以将血红蛋白值稳定在10至12 g/dl之间。接受r-HuEPO治疗的患者需要定期医疗监督，因为——随着血细胞比容增加——可能会出现高血压和动静脉瘘血栓形成。在一些研究中观察到血清肌酐和钾略有升高。
